Matthew Kibble

Member, CNAS Board of Advisors

Founder and Managing Partner, DYNE Asset Management

  • Press:

Mr. Kibble is the Founder and Managing Partner of DYNE Asset Management, an alternative asset management company focused on generating exceptional financial returns by investing in national security technology and supply chain resiliency for the U.S., U.K. and Australian technology.

Matthew began his career as an accountant at Ernst and Young and spent over five years with JPMorgan Chase in the Consumer, Healthcare and Retail Investment Banking and Institutional Asian Equities and Derivatives divisions before launching the Latin American investment vehicle Everlight Capital. In 2013 he joined the private investment vehicle Cap-Meridian Ventures as a partner with a broad mandate to invest in numerous asset classes globally, mainly disruptive technologies with superior operations teams. Early stage investments included: Casper, Compass, Credible, Modern Meadow, Palantir, and Peloton.In 2016, Matthew began to focus on his private investment group Kibble Holdings (“KH”). With a similar thesis to Cap-Meridian Ventures but now more opportunistic.

In 2020, Matthew joined forces with the former Consul-General of Australia to New York, Mr Alastair Walton, to form DYNE Capital originally for the sole purpose to structure and invest in an opportunity to help address a US supply chain issue centered around cobalt and CREE. From this, DYNE Asset Management evolved to focus on a broader thesis around US supply chain and AUKUS defense / national security.

Matthew is currently a director of Eaton Hemp, Kibble Pet, Certane and has been a director of publicly listed Andina Acquisition Corporation II and III (a successful SPAC franchise). He holds a Bachelor of Commerce degree, majoring in Finance and Accounting, a Bachelor of Science degree, majoring in Biomedical Sciences, both from the University of Queensland, Australia. He is an Exempt Reporting Advisor subject to certain portions of the Investment Advisers Act of 1940 and has held FINRA Series 7 and Series 63 licenses.

Support CNAS